



MARY BIRD PERKINS
CANCER CENTER™

CAR T-CELL THERAPY PROGRAM

**Advanced Immunotherapy for
Blood Cancers - Now Available**



Andrew Dalovisio, MD
Director of Myeloma, Lymphoma,
and Cellular Therapy Program

Mary Bird Perkins Cancer Center is offering FDA-approved CAR-T (Chimeric Antigen Receptor T-cell) therapies for eligible patients with relapsed or refractory hematologic malignancies — including outpatient treatment pathways for appropriate candidates.

CAR-T therapy uses a patient’s own immune cells, engineered to recognize and destroy cancer cells, providing a highly targeted treatment option when standard therapies have failed.

Mary Bird Perkins has been accredited as a treatment site for Kite CAR T-cell therapy products.



Approved Indications *(Based on current FDA approvals and clinical criteria)*

- Diffuse Large B-Cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Follicular Lymphoma
- B-cell Acute Lymphoblastic Leukemia (ALL)
- Multiple Myeloma
**Available Q2 2026*

When to Consider Referral

Patients who:

- Had early relapsed or refractory disease
- Are not responding to conventional chemotherapy or immunotherapy
- Have adequate performance status and organ function
- May benefit from advanced cellular therapy options

Our team will determine eligibility and guide next steps.

Program Highlights

- **Outpatient and inpatient CAR-T treatment options**
- Dedicated multidisciplinary CAR-T team
- Rapid referral review (typically within 24–48 hours)
- Comprehensive toxicity monitoring and supportive care
- Ongoing communication with referring providers

We partner closely with you throughout evaluation, treatment, and follow-up.

How to Refer

Fax: (225) 215-1661 • Phone: (225) 767-1311

Please include recent clinical notes, pathology, and treatment history when available.

For questions, please contact **Shannon Hyde** at **(225) 413-5384**